Spexin-mediated mitigating effects on obesity and MASLD in mice on HFD and in PA-induced HepG2 cells were eradicated by M871, proving that spexin, a known GalR2/3 agonist, produces its beneficial effect through the activation of GalR2 (Wang et al., 2022). Here, GALR2 is linked to metabolic dysfunction-associated steatotic liver disease.